As of Friday close, Viking Therapeutics Inc.’s (NASDAQ:VKTX) stock was down -$0.43, moving down -3.23 percent to $12.88. The average number of shares traded per day over the past five days has been 1,718,640 shares. 1 time new highs have been achieved over the past 5 days, with a -$1.89 fall in that time frame. In the last twenty days, the average volume was 1,786,840, while in the previous 50 days, it was 1,695,010.
Since last month, VKTX stock retreated -10.18%. Shares of the company fell to $12.77 on 09/22/23, the lowest level in the past month. A 52-week high of $25.72 was reached on 05/23/23 after having rallying from a 52-week low of $2.53. Since the beginning of this year, VKTX’s stock price has risen by 37.02% or $3.48, and marked a new high 29 times. However, the stock has declined by -49.92% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
VKTX stock investors should be aware that Viking Therapeutics Inc. (VKTX) stock had its last reported insider trading activity 130 days ago on May 16. Rowland Charles A Jr, the Director of the company, disposed of 40,000 shares for $25.00 on May 16. It resulted in a $1,000,000 divestment by the insider. MACARTNEY LAWSON sold 16,000 shares at an average price of $24.00 on May 16. The insider now owns 47,965 shares following the transaction. On May 01, President & CEO Lian Brian sold 45,000 shares at $22.45 apiece. The transaction was valued at $1,010,250.
Financial Health
In the three months ended June 29, Viking Therapeutics Inc.’s quick ratio stood at 29.60, while its current ratio was 29.60, showing that the company is able to pay off its debt.
While analysts expected Viking Therapeutics Inc. to report -$0.19 quarterly earnings, the actual figure was -$0.19 per share. The liabilities of Viking Therapeutics Inc. were 14.58 million at the end of its most recent quarter ended June 29, and its total debt was $1.41 million. The value of shareholders’ equity is $100.03 million.
Technical Picture
This quick technical analysis looks at Viking Therapeutics Inc.’s (VKTX) price momentum. With a historical volatility rate of 25.32%, the RSI 9-day stood at 26.87% on 22 September.
With respect to its five-day moving average, the current Viking Therapeutics Inc. price is down by -12.80% percent or -$1.89. At present, VKTX shares trade -5.22% below its 20-day simple moving average and -41.77% percent below its 100-day simple moving average. However, the stock is currently trading approximately -18.17% below its SMA50 and +224.43% above its SMA200.
Stochastic coefficient K was 5.45% and Stochastic coefficient D was 10.46%, while ATR was 0.72. Given the Stochastic reading of 3.06% for the 14-day period, the RSI (14) reading has been calculated as 34.10%. As of today, the MACD Oscillator reading stands at -0.93, while the 14-day reading stands at -1.24.
With a median target price of $34.00, the current consensus forecast for the stock is $28.00 – $40.00. Based on these forecasts, analysts predict Viking Therapeutics Inc. (VKTX) will achieve an average price target of $33.80.
